Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172938 | 0.98 | TSHR (0.50) | LMNATSHRNFKB1PMP22CYP2D6 | |
| SCHEMBL234493 | 0.93 | LMNA (0.43) | LMNATSHRNFKB1PMP22CYP2D6 | |
| SCHEMBL367757 | 0.86 | GRM8 (0.42) | LMNATSHRBLMTHRBKMT2A | |
| SCHEMBL3485787 | 0.77 | ALDH1A1 (0.57) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL3473015 | 0.77 | TSHR (0.50) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL454023 | 0.77 | LMNA (0.58) | LMNATSHRNFKB1PMP22CYP2D6 | |
| SCHEMBL28008096 | 0.76 | ALDH1A1 (0.47) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL3875964 | 0.76 | LPAR3 (0.54) | GABBR2GABRR1GABBR1 | |
| Adipic Acid SCHEMBL4637028 | 0.75 | LMNA (0.73) | LMNATSHRNFKB1PMP22CYP2D6 | |
| SCHEMBL4527282 | 0.75 | TSHR (0.60) | LMNATSHRNFKB1PMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12194201-B2 | Silica nanoparticle doped conductive polymer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-01-14 | — | — | US | claimed |
| CN-102614514-B | GLP-1 acceptor agonists used for treating pains | WANG YONGXIANG | 2014-12-10 | — | — | CN | claimed |
| CN-102614514-A | GLP-1 acceptor agonists used for treating pains | YONGXIANG WANG | 2012-08-01 | — | — | CN | claimed |
| EP-4097145-B1 | REDUCTION OF ADSORPTION | LEUKOCARE AG (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12428456-B2 | Peptide directed protein knockdown | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2025-09-30 | — | — | US | disclosed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12329815-B2 | Acoustic driven drug delivery systems | UNIVERSITY OF OTAGO (NZ) | 2025-06-17 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-12194201-B2 | Silica nanoparticle doped conductive polymer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024227008-A1 | FLUORESCENT SENSORS AND METHODS OF MAKING AND USING | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | disclosed |
| US-5498610-A | Neuroprotective indolone and related derivatives | PFIZER INC. (US) | 1996-03-12 | — | — | US | disclosed |
| WO-1996006081-A1 | NEUROPROTECTIVE 3-(PIPERIDINYL-1)-CHROMAN-4,7-DIOL AND 1-(4-HYDROPHENYL)-2-(PIPERIDINYL-1)-ALKANOL DERIVATIVES | PFIZER INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995020587-A1 | NEUROPROTECTIVE CHROMAN COMPOUNDS | PFIZER INC. (US) | 1995-08-03 | — | — | WO | disclosed |
| US-5436255-A | Method of treating diseases susceptable to treatment by blocking NMDA-receptors | PFIZER INC. (US) | 1995-07-25 | — | — | US | disclosed |
| US-5192751-A | Administering a decahydroisoquinoline derivative | ELI LILLY AND COMPANY (US) | 1993-03-09 | — | — | US | disclosed |
| US-4483853-A | ANTICONVULSANTS | COLLINS JAMES F | 1984-11-20 | — | — | US | disclosed |
| US-4483853-A | ANTICONVULSANTS | COLLINS JAMES F | 1984-11-20 | — | — | US | disclosed |
| US-4477391-A | Amino acid isomers, their production and their medicinal use | COLLINS JAMES F (GB) | 1984-10-16 | — | — | US | disclosed |
| US-4477391-A | Amino acid isomers, their production and their medicinal use | COLLINS JAMES F (GB) | 1984-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | LMNA 1380/4885TSHR 2764/4885NFKB1 3632/4885 |
| US-12329815-B2 | Acoustic driven drug delivery systems | PARK7, NLN, OPA1 | LMNA 1549/4885TSHR 3176/4885NFKB1 4386/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | LMNA 1380/4885TSHR 2764/4885NFKB1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.